CoChat

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Open access
Patalon, Tal, Saciuk, Yaki, Peretz, Asaf, Perez, Galit, Lurie, Yoav, Maor, Yasmin, Gazit, Sivan · 2022 · Nature Communications

Published version of a preprint

The DOI matches its Crossref record; 24 of the 30 references it cites were found in a registry or an index; 11 of the 12 sources its claims cite were checked for support.

Abstract

The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.

Overview

CoChat Summary

TL;DR

In a retrospective test-negative case-control study in Maccabi Healthcare Services during the Omicron-dominant period in January 2022, third-dose BNT162b2 effectiveness against infection declined from 53.4% one month after vaccination to 16.5% three months after vaccination, relative to August 2021 booster recipients. Waning against severe disease was not statistically significant, with the authors noting small numbers.

Key findings

  • Among 546,924 PCR tests by 389,265 eligible MHS members from January 1–21, 2022, adjusted third-dose VE against SARS-CoV-2 infection compared with August 2021 booster recipients was 53.4% (95% CI 47.7–58.6) for December 2021 vaccinees, 35.7% (29.8–41.2) for November 2021 vaccinees, 16.5% (13.0–19.9) for October 2021 vaccinees, and 3.6% (0.6–6.5) for September 2021 vaccinees.
  • In the marginal-effectiveness analysis versus two-dose-only vaccinees, booster effectiveness against infection peaked at 59.4% (95% CI 54.9–63.5) one month after vaccination and declined to 16% (95% CI 12.3–19.5) five months after vaccination.
  • For severe disease, the main analysis did not reach significance for decreasing VE against hospitalization or death as time since inoculation increased; the paper states the raw numbers were too small for a reliable conclusion. Marginal severe-disease VE declined from 72.2% (95% CI 37.8–87.6) at 3 months to 54.5% (95% CI 13.4–76.1) at 5 months, again with small numbers.
  • During the Omicron period, 101,737 breakthrough infections and 482 breakthrough infections resulting in hospitalization or death were detected; among August 2021 booster recipients there were 30,870 infections, 208 hospitalizations, and 9 deaths, while among December 2021 booster recipients there were 1,082 infections, 4 hospitalizations, and zero deaths.

Methods

  • Retrospective test-negative case-control study using Maccabi Healthcare Services data; included MHS members aged 16 or older who received at least two BNT162b2 doses by August 1, 2021, with outcomes evaluated January 1–21, 2022, an Omicron-dominant period in Israel.
  • Cases were PCR-positive persons or persons with severe COVID-19 during follow-up; controls were PCR-negative persons; 1:1 matching was based on sex, age group, geographic statistical area, calendrical week of testing, and month of second-dose receipt; conditional logistic regression was adjusted for comorbidities, and VE was calculated as 100% × [1 − odds ratio].
  • Additional analyses included an unmatched GEE logistic regression allowing multiple negative tests, inclusion of tests 0–6 days after a fourth dose, changing the reference group to two-dose-only vaccinees, inclusion of individuals with hybrid immunity, and assessment of control-group representativeness.

Limitations

  • Stated in the paper: potential bias from healthcare-related testing behavior, especially with changing Israeli testing policies during the Omicron surge; the August 2021 comparison group was generally older and sicker; residual confounding by indication was considered less likely after matching/adjustment, though effect modification was seen for obesity; Omicron dominance meant waning against other strains could not be evaluated; and the database lacked reason for testing.
  • Stated in the paper: severe-disease analyses were limited by small numbers of hospitalizations and deaths, preventing reliable conclusions about waning against severe outcomes.
  • Evident from the text: the observational design cannot establish causation, and the fourth-dose exclusion/sensitivity analyses indicate that vaccination-status definitions and timing choices may affect estimates.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-022-30884-6

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Daily SARS-Cov-2 infection and SARS-Cov-2-related hospitalization rates per 10,000 persons. The graph exemplifies Omicron’s spread, with a rapid increase in infections and hospitalizations, peaking in mid-January.
Fig. 1 Daily SARS-Cov-2 infection and SARS-Cov-2-related hospitalization rates per 10,000 persons. The graph exemplifies Omicron’s spread, with a rapid increase in infections and hospitalizations, peaking in mid-January.CC BY · PubMed Central
Fig. 2 Adjusted odds ratio (left) and vaccine effectiveness (right) against SARS-CoV-2 breakthrough infection. Left: Data are presented as adjusted OR, as a function of time in months (calendrical month) since the administration of the third dose, with error bars indicating the corresponding 95% Wald’s C.I. Right: Data are presented as adjusted VE, as a function of time in months (calendrical month) since the administration of the third dose, with error bars indicating the corresponding 95% Wald’s C.I.
Fig. 2 Adjusted odds ratio (left) and vaccine effectiveness (right) against SARS-CoV-2 breakthrough infection. Left: Data are presented as adjusted OR, as a function of time in months (calendrical month) since the administration of the third dose, with error bars indicating the corresponding 95% Wald’s C.I. Right: Data are presented as adjusted VE, as a function of time in months (calendrical month) since the administration of the third dose, with error bars indicating the corresponding 95% Wald’s C.I.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 1 Not checked · 27 Own results and interpretations

18 more claims

Create a free account to see all 34 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 24 references

Cited by

See all 155

Metadata

Authors
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S.
Affiliations
  • Maccabi Healthcare Services (IL)
  • Shaare Zedek Medical Center (IL)
Corresponding author
Patalon, Tal
Venue
Nature Communications
Published
2022-06-09
Volume
13
Issue
1
Pages
3203-3203
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4281648214
Cited by
143
References
30
Citations by year
2026: 4 · 2025: 15 · 2024: 25 · 2023: 56 · 2022: 43
FWCI
16.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
BNT162b2 mRNA vaccine, COVID-19 vaccines, booster vaccination, waning vaccine effectiveness, Omicron variant, COVID-19 pandemic, test-negative case-control, PCR testing, duration of protection
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Retrospective Studies, RNA, Messenger

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. https://app.cochat.ai/papers/10.1038/s41467-022-30884-6
The paper
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022). Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nature Communications. https://doi.org/10.1038/s41467-022-30884-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.